Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Arbutus Biopharma Corporation (ABUS) has a Wall Street consensus price target of $8.50, based on estimates from 10 covering analysts. With the stock currently trading at $4.66, this represents a potential upside of +82.4%. The company has a market capitalization of $895M.
Analyst price targets range from a low of $8.50 to a high of $8.50, representing a 0% spread in expectations. The median target of $8.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ABUS trades at a trailing P/E of -12.3x. Analysts expect EPS to grow +27.4% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ABUS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for ABUS is $8.5, representing 82.4% upside from the current price of $4.66. With 10 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ABUS has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $8.5 implies 82.4% upside from current levels.
ABUS's current price is $4.66 with a consensus target of $8.5 (82.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8.5 for ABUS, while the most conservative target is $8.5. The consensus of $8.5 represents the median expectation. These targets typically reflect 12-month expectations.
ABUS is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ABUS stock forecast based on 10 Wall Street analysts shows a consensus price target of $8.5, with estimates ranging from $8.5 (bear case) to $8.5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ABUS, with a "Buy" consensus rating and $8.5 price target (82.4% upside). 8 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ABUS analyst price targets range from $8.5 to $8.5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $8.5 consensus represents the middle ground.